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a b s t r a c t
The adult mammalian brain contains multiple populations of endogenous progenitor cell types. However,
following CNS trauma or disease, the regenerative capacity of progenitor populations is typically insufﬁcient
and may actually be limited by non-permissive or inhibitory signals in the damaged parenchyma.
Remyelination is the most effective and simplest regenerative process in the adult CNS yet is still insufﬁcient
following repeated or chronic demyelination. Our previous in vitro studies demonstrated that ﬁbroblast
growth factor receptor 1 (FGFR1) signaling inhibited oligodendrocyte progenitor (OP) differentiation into
mature oligodendrocytes. Therefore, we questioned whether FGFR1 signaling may inhibit the capacity of OP
cells to generate oligodendrocytes in a demyelinating disease model and whether genetically reducing FGFR1
signaling in oligodendrocyte lineage cells could enhance the capacity for remyelination. FGFR1 was found to
be upregulated in the corpus callosum during cuprizone mediated demyelination and expressed on OP cells
just prior to remyelination. Plp/CreER T:Fgfr1ﬂ/ﬂ mice were administered tamoxifen to induce conditional Fgfr1
deletion in oligodendrocyte lineage cells. Tamoxifen administration during chronic demyelination resulted in
reduced FGFR1 expression in OP cells. OP proliferation and population size were not altered one week after
tamoxifen treatment. Tamoxifen was then administered during chronic demyelination and mice were given a
six week recovery period without cuprizone in the chow. After the recovery period, OP numbers were reduced
and the number of mature oligodendrocytes was increased, indicating an effect of FGFR1 reduction on OP
differentiation. Importantly, tamoxifen administration in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice signiﬁcantly promoted
remyelination and axon integrity. These results demonstrate a direct effect of FGFR1 signaling in oligodendrocyte
lineage cells as inhibiting the repair capacity of OP cells following chronic demyelination in the adult CNS.
Published by Elsevier Inc.

Introduction
Optimization of the endogenous neural stem and progenitor cell
capacity for repair of the adult CNS is a high priority among regenerative
medicine approaches for diverse forms of CNS injury and disease.
Remyelination is an excellent example of successful endogenous cell
repair in the adult CNS and a relatively simple model for interrogating
the cellular and molecular interactions that impact the effectiveness of
regenerative responses from neural stem and progenitor cells. In the
mammalian brain, endogenous neural stem cells of the subventricular
zone and oligodendrocyte progenitor (OP) cells of the white matter can
effectively generate new oligodendrocytes and exhibit extensive
remyelination after a transient episode of demyelination (Aguirre et al.,
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2007; Murtie et al., 2005b; Nait-Oumesmar et al., 2008). However, with
repeated or prolonged episodes of demyelination, OP cells become
depleted and remyelination becomes less effective (Armstrong et al.,
2006; Mason et al., 2004).
Growth factors, cytokines, and extracellular matrix molecules that
can inﬂuence the regenerative responses of endogenous neural stem and
OP cells can be associated with demyelination and the associated
pathological features, such as reactive astrogliosis, microglia/macrophage
activation, and inﬂammatory cell inﬁltration. Modifying the molecular
signals of the lesion environment may attenuate inhibitory signals and
promote endogenous cell regenerative responses. Our previous analyses
of ﬁbroblast growth factor 2 (FGF2), which is upregulated in areas of
demyelination, have demonstrated proof-of-concept that genetic deletion of Fgf2 can signiﬁcantly improve spontaneous remyelination as well
as reduce axonal damage associated with chronic demyelination
(Armstrong et al., 2006, 2002; Tobin et al., 2011).
To better design approaches that can improve endogenous cell
regenerative responses, it is important to identify the speciﬁc
mechanisms of action and potential therapeutic targets. In vitro studies
demonstrated a signiﬁcant role of ﬁbroblast growth factor receptor 1
This article is a U.S. government work, and is not subject to copyright in the United States.
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(FGFR1) in mediating FGF2 inhibition of OP cell differentiation into
oligodendrocytes (Zhou et al., 2006). The current studies evaluate
FGFR1 expression corresponding with FGF2 upregulation in cuprizone
induced demyelination of the corpus callosum (CC). We then use
Plp/CreERT:Fgfr1ﬂ/ﬂ mice to test FGFR1 as a key component regulating
oligodendrocyte lineage cell regenerative responses mediating remyelination. Cuprizone ingestion in mice produces reproducible and
extensive demyelination, especially within the caudal CC (Wu et al.,
2008; Xie et al., 2010), with pathological characteristics of oligodendrocyte loss that are shared with MS types III and IV (Liu et al., 2010;
Lucchinetti et al., 1999). Cuprizone feeding can produce a prolonged
period of experimental demyelination that models chronic demyelination effects including depletion of the OP cell population and inefﬁcient
spontaneous remyelination (Armstrong et al., 2006; Mason et al., 2004).
Analysis of regenerative processes and remyelination is facilitated by
the ability to remove the cuprizone demyelinating agent from the diet.
Furthermore, use of the Plp/CreERT construct provides conditional Cre
recombinase expression to evaluate a direct effect of FGFR1 signaling in
oligodendrocyte lineage cells and tamoxifen induction to target the
FGFR1 gene deletion within the disease time course.
Materials and methods
Mice and cuprizone demyelination
All experimental procedures using mice were approved by the USUHS
Institutional Animal Care and Use Committee. C57BL/6 mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). Plp/CreERT
mice (Doerﬂinger et al., 2003) were derived from breeding pairs
purchased from The Jackson Laboratory (B6.Cg-Tg(Plp1-cre/ESR1)
3.16Pop/J; Bar Harbor, ME). Mice with a ﬂoxed Fgfr1 allele were
generated by Dr. Juha Partanan and provided through Dr. Flora Vaccarino
(Yale University, New Haven, CT) (Pirvola et al., 2002). Mice with a ﬂoxed
platelet-derived growth factor receptor alpha (Pdgfrα) allele were
provided by Dr. Michelle Tallquist (Tallquist and Soriano, 2003). Z/AP
dual reporter mice (Tg(CAG-Bgeo/ALPP)1Lbe/J; The Jackson Laboratory,
Bar Harbor, ME) were provided by Dr. Tudor Badea (Johns Hopkins
University, Baltimore, MD) (Lobe et al., 1999). All mouse lines were
backcrossed to the C57BL/6 background. Male mice were fed ad libitum a
diet of 0.2% (w/w) cuprizone (oxalic bis-(cyclohexylidenehydrazide);
Sigma-Aldrich, Milwaukee, WI) mixed into milled chow pellets (Harlan
Teklad, Madison, WI) beginning at 8 wks of age.

18 s RNA). The average CT values for this set of housekeeping genes
ranged from 22.6 (0 wk, no cuprizone) to 23.8 (12 wk cuprizone plus
6 wk recovery), indicating relative stability across the disease time
course. Fold changes in gene expression throughout the cuprizone
time course were calculated relative to pre-treatment (0 wk) CT
values, with a detection threshold set at 35 cycles. Differential gene
expression across the cuprizone time course and within the gene set
was analyzed using Gene Pattern 2.0 software (Gould et al., 2006;
Reich et al., 2006).

Detection of Cre recombinase activity using Z/AP dual reporter mice
Plp/CreERT driven expression of Cre recombinase and the tamoxifen
treatment protocol were tested by expression of alkaline phosphatase
(AP) from recombination of the dual reporter in Z/AP mice.
PLP/CreER T:Z/AP mice were treated with tamoxifen at 4 wks of age,
after the completion of developmental myelination, and sacriﬁced
two weeks later for analysis of AP in coronal brain sections (Fig. 1A).
Tamoxifen (4-hydroxytamoxifen; Sigma, St. Louis, MO) was administered by intraperitoneal injection (0.8 mg every 12 h for 5 days;
total 8 mg). To eliminate endogenous AP activity tissue sections were
incubated in PBS for heat inactivation (65 °C for 30 min) followed by
incubation in levamisole for 10 min. AP reporter activity was detected
using an NBT/BCIP (DAKO, Carpentaria, CA) substrate reaction.

Immunohistochemistry of Plp/CreER T driven expression of Cre in
oligodendrocytes
Transverse sections of spinal cord from Plp/CreERT mice perfused at
6 wks of age were immunostained to conﬁrm Cre expression in
oligodendrocytes. Immunoﬂuorescence for Cre (rabbit IgG polyclonal
anti-Cre; Novagen, San Diego, CA) detected with goat anti-rabbit IgG
Alexa Fluor 488 (Invitrogen, Carlsbad, CA) was combined with CC1
immunolabeling (mouse IgG monoclonal; Oncogene Research Products,
Cambridge, MA) detected with donkey anti-mouse IgG F(ab)2 fragment
conjugated with Cy3 (Jackson ImmunoResearch).

Expression analysis of FGF family of signaling components in C57BL/6
mice
Male C57BL/6 mice were analyzed at 8 wks of age prior to the start
of cuprizone (0 wk), at 3-wk intervals throughout the 12-wk
cuprizone treatment, or after a 6-wk recovery period. The CC was
micro-dissected on ice, transferred to TRIZOL reagent (GIBCO-BRL,
Grand Island, NY) and processed for RNA extraction. Following Turbo
DNAse (Ambion, Foster City, CA) treatment to remove genomic DNA
contamination, RNA samples from 3 mice per condition were pooled
as template for cDNA synthesis using the RT2 First Strand cDNA
synthesis kit (SABiosciences, Frederick, MD). For each time point
cDNA was generated from 1.5 μg of RNA template (0.5 μg/mouse from
each of 3 mice) and was run on triplicate plates. Gene expression was
quantiﬁed using real-time PCR custom arrays with SYBR Greenoptimized primers and internal controls for effective PCR reactions
and genomic DNA contamination (SABiosciences) run on an ABI 7500
real time PCR cycler. Differences in the number of cycles to threshold
(CT) were analyzed using the ΔΔCT method. Values were normalized
to an average of housekeeping values obtained for the same samples
run on a plate of 12 standardized housekeeping genes that included
high and low abundance transcripts (SABiosciences; genes Actb, B2m,
Gusb, Hsp90ab1, Ldhal6b, Nono, Ppia, Rpl13a, Tfrc, Tbp, Hprt1, Act1b,

Fig. 1. Timing of tamoxifen treatment within experimental protocols. Mice were
administered tamoxifen to induce nuclear translocation of the Cre recombinase fusion
protein and subsequent deletion of ﬂoxed gene alleles. Different timing of tamoxifen
administration was used to evaluate Cre activity driven from the proteolipid protein
(PLP) gene promoter (A), for light microscopic (LM) analysis of chronic demyelination
and recovery (B) and for electron microscopic analysis (EM) of during chronic
demyelination. Tamoxifen was administered by intraperitoneal injections of 0.8 mg
every 12 h for 5 days with a total dose of 8 mg. Cuprizone feeding began at 8 wks of age
and continued for up to 12 wks, i.e. 20 wks of age. Lines are not drawn to scale for
speciﬁc number of wks shown by numbers.
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Tamoxifen induction of conditional deletion of Fgfr1or Pdgfrα
Tamoxifen treatment was used to induce conditional deletion of
Fgfr1 in oligodendrocyte lineage cells of Plp/CreER T:Fgfr1 ﬂ/ﬂ mice or
Pdgfrα in Plp/CreER T:Pdgfrα ﬂ/ﬂ mice. Tamoxifen was administered, as
noted above for Z/AP mice, starting on week 8 or week 10 of cuprizone
treatment (Figs. 1B, C). Control mice of the same genotype were
administered sunﬂower oil vehicle only. For analysis of cell proliferation, mice were given two injections of bromodeoxyuridine (BrdU;
Sigma, 200 mg/kg i.p.), each 2 h apart, and sacriﬁced at the end of the
four-hour period for BrdU incorporation, as previously detailed
(Armstrong et al., 2002). Mice were perfused with 3% paraformaldehyde for immunohistochemistry and in situ hybridization of coronal
brain sections. FGFR1 was detected using a mouse monoclonal FGFR1
antibody clone 19B2 (Upstate Biotech., Lake Placid, NY). PDGFαR,
NG2, CC1 and myelin oligodendrocyte glycoprotein (MOG) immunolabeling were performed as previously detailed (Armstrong et al.,
2006; Murtie et al., 2005b). Preparation of digoxigenin labeled
riboprobes for PLP and PDGFαR and in situ hybridization with
detection by reaction in NBT/BCIP substrate (DAKO, Carpinteria, CA)
along with BrdU detection was performed as previously detailed
(Armstrong et al., 2002; Redwine and Armstrong, 1998).
Images of in situ hybridization and immunostaining results were
captured with a Spot 2 CCD digital camera using Spot Advanced image
acquisition software (Diagnostic Instruments, Sterling Heights, MI).
Images were prepared as panels using Adobe Photoshop 7 (San Jose, CA).
Quantiﬁcation of immunohistochemistry and in situ hybridization
results included at least 3 sections per mouse and 3 mice per condition.
As previously reported (Armstrong et al., 2002), OP cells were counted
and areas measured using Spot software, cells expressing PLP mRNA
were quantiﬁed using unbiased stereologic morphometric analysis, and
MOG immunolabeling was quantiﬁed using pixel thresholding of
myelinated areas using Metamorph software (Molecular Devices,
Downingtown, PA).
Ultrastructural analysis of myelin and axon pathology
Following treatment with cuprizone and tamoxifen (Fig. 1C), mice
were perfused with 2% paraformaldehyde/3% acrolein for processing
of parasagittal sections for electron microscopy and for alternate
sections to be process for immunohistochemistry, as previously
described (Xie et al., 2010). Cuprizone pathology differs along the
rostro-caudal extent of the CC with the most extensive pathology
observed in the caudal CC (Wu et al., 2008; Xie et al., 2010). Therefore,
analyses focused on the caudal CC (−1.5 to − 2.0 mm relative to
bregma) (Xie et al., 2010). Sections were examined in a Philips CM100
transmission electron microscope and images were imported into
MetaMorph (Molecular Devices, Downington, PA) for quantitative
analysis, including axon diameter and myelin thickness. Myelin
thickness was calculated from the average of radial measurements
at 4 points per sheath, avoiding areas of tongue processes or ﬁxation
artifact. Axons diameters were calculated from measurement of the
axon circumference. Axons with diameters typical of unmyelinated
ﬁbers (b0.3 μm) were excluded from analysis in order to more
speciﬁcally follow the changes associated with demyelination and
remyelination within the myelinated ﬁber population (Mason et al.,
2001; Tobin et al., 2011; Xie et al., 2010).
Immunohistochemical analysis of axon integrity
Alternate tissue sections were processed for electron microscopy
(above) or immunohistochemistry. Parasagittal ﬂoating 40 μm sections were double-immunostained for total neuroﬁlament (NF200,
rabbit polyclonal pan-neuroﬁlament antibody, Chemicon, Billerica,
MA) and non-phosphorylated neuroﬁlament (SMI-32, mouse monoclonal IgG; Covance) to evaluate axonal integrity (Tobin et al., 2011).
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NF200-positive and SMI-32-positive cross-sectional proﬁles were
counted on high magniﬁcation images acquired on a Zeiss Pascal
confocal microscope with a 63× objective and then imported into
Adobe Photoshop 7. Axonal damage was estimated as the percentage
of SMI-32-positive proﬁles among all neuroﬁlament-positive proﬁles
counted.
Statistical analysis
Prism (Graph Pad Software) was used for statistical analyses and
production of graphs. Across cuprizone time points, values for a single
mouse genotype were examined using one-way ANOVA whereas two
genotypes were compared using two-way ANOVA. For gene expression
pattern analysis, one-way ANOVA across cuprizone stages was followed
by analysis of each time point with a one sample t-test comparison to a
theoretical mean of 1.000 (i.e. no fold change). Values of two genotypes
or conditions at a single time point were compared using a t-test.
Scattergraph data was analyzed by linear regression and comparison of
the slopes and intercepts. A level of 0.05 was used for the overall test of
signiﬁcance. Values are expressed as the mean± standard error of the
mean.
Results
Expression pattern of FGF family of ligands and receptors throughout the
cuprizone disease time course
Quantitative RT-PCR custom arrays of the FGF family, along with
selected markers of distinct cell types, were used to examine
expression and potential relevance to FGF signaling throughout the
course of cuprizone demyelination and recovery. Genes expressed in
reactive astrocytes, microglia/macrophages, and OP cells increase
during demyelination and separate into a distinct hierarchal cluster
from genes that decrease with cuprizone induced loss of oligodendrocytes and myelin (Fig. 2; Table 1). The appropriate hierarchical
clustering of cell type speciﬁc markers demonstrates ﬁdelity of the
processing and analysis methods for detecting expression changes
throughout the disease course (Fig. 2; gray). FGFR1, FGF2, and FGF12
align within the cluster of markers for astrocytes, microglia, and OP
cells indicating potential expression in reactive cell types in contrast
to mature oligodendrocytes. Alignment of FGFR1 within the same
cluster as FGF2 is supportive of FGFR1 as relevant to FGF2 signaling in
this context (Fig. 2; yellow cluster). Although FGF12 also falls within
the FGFR1 cluster, FGF12 acts independently of FGFRs and therefore is
not a relevant partner for FGFR1 (Itoh and Ornitz, 2008). Several FGF
family ligands (FGF4, 6, 14–16, 21) did not rise above the detection
threshold at any time points (not shown).
FGFR1 regulation of recovery following chronic demyelination
Plp/CreER T mice were crossed with ﬂoxed alleles of Fgfr1 to directly
examine the role of FGFR1 in OP cells and the generation of
oligodendrocytes during remyelination. The Plp/CreER T mouse design
employs tamoxifen administration to induce deletion of ﬂoxed alleles
at desired stages of chronic disease progression to minimize the
potential for compensatory effects during development or earlier
stages of disease. Effectiveness of the tamoxifen procedure and dose
for induction of Cre translocation and recombination in cells
contributing to myelination was demonstrated using Plp/CreER T:Z/AP
reporter mice (Fig. 3A). Localization of Cre protein in oligodendrocytes was conﬁrmed by immunohistochemical co-localization with
CC1 (Figs. 3B–D). Although PLP promoter activity is highest in mature
oligodendrocytes, sufﬁcient expression in Plp/CreER T mice to drive
effective recombination in OP cells was demonstrated when crossed
to ﬂoxed Pdgfrα mice. Tamoxifen administration (Fig. 1A) resulted in
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Fig. 2. Expression proﬁle for FGF family of ligands and receptors throughout the course of cuprizone demyelination and recovery. Heat map to show differential gene expression
following quantitative RT-PCR of RNA isolated from the CC of C57BL/6 mice at intervals noted throughout the cuprizone treatment and recovery periods. For each gene the lowest
values are represented by dark blue and progressing through light blue and pinks to reds for the highest values. Columns show results of technical triplicates run on separate plates
for each time point (N = 3 mice per time point). Genes that are characteristic of distinct cellular response are noted (gray highlights). Associations among gene patterns across the
disease time course are identiﬁed by heirarchical cluster analysis. Genes that align within the heirarchical cluster corresponding with FGF2 (yellow highlights) have values of fold
increases and statistical comparisons shown in Table 1.

a 35% reduction of PDGFαR expression among NG2 cells in Plp/CreER T:
Pdgfrα ﬂ/ﬂ mice (p = 0.0002; Fig. 3E).
Next, expression of FGFR1 in the CC of chronically demyelinated
mice was conﬁrmed by immunohistochemistry (Fig. 4). Of importance relative to the potential to regulate remyelination, FGFR1 was
expressed among OP cells identiﬁed by NG2 immunolabeling in the
CC of mice at 12 wks of cuprizone treatment prior to the recovery
phase (Figs. 4A–C). To reduce FGFR1 expression at this corresponding
period, Plp/CreER T:Fgfr1 ﬂ/ﬂ mice were administered tamoxifen or oil
(vehicle) after 10 wks of cuprizone and continued on cuprizone
through 12 wks prior to perfusion (Fig. 1B). Tamoxifen treatment
resulted in a 33% reduction of FGFR1 expression among NG2 cells in
the chronically demyelinated CC as compared to vehicle-treated mice
(p = 0.0105; Fig. 4D). In these mice, the OP population was also
identiﬁed by in situ hybridization for PDGFαR and proliferation was
examined by BrdU incorporation during a 4-h terminal pulse at the
end of the 12 wks of cuprizone (Figs. 4E–F). Proliferation of OP cells

was not signiﬁcantly altered with tamoxifen treatment (p N 0.05;
Fig. 4F). In addition, tamoxifen treatment did not signiﬁcantly change
the number of OP cells in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice examined after
12 wks of cuprizone (Fig. 4G). However, when a 6-wk recovery period
was added after 12 wks of cuprizone, the OP population was reduced
in the tamoxifen treated mice as compared to controls (p b 0.05;
Fig. 4G). Over this 6-wk recovery period, the reduced OP population
could result from decreased OP proliferation or an increase of OP cells
differentiating into mature oligodendrocytes.
The role of FGFR1 in the oligodendrocyte lineage during the
recovery from demyelination was further examined using in situ
hybridization for PLP to identify oligodendrocytes and immunohistochemistry for MOG to estimate the extent of remyelination (Fig. 5).
Plp/CreER T:Fgfr1 ﬂ/ﬂ mice were administered tamoxifen or oil (vehicle)
starting after 10 wks of cuprizone, continued on cuprizone through
12 wks, and then allowed a 6-wk recovery period on normal chow
prior to perfusion (Fig. 1B). In situ hybridization for PLP mRNA

Table 1
Quantitative RT-PCR of cell type markers and signaling components clustered with FGF2.
Gene

0 wk
No cup

3 wk cup

6 wk cup

9 wk cup

12 wk cup

12 wk cup
6 wk off

ANOVA
p value

Vim
GFAP
Mac1
NG2
PDGFRα
FGF2
FGF12
FGFR1
MBP
PLP
MAG

1.04 ± 0.22
1.08 ± 0.30
1.00 ± 0.03
1.02 ± 0.14
1.03 ± 0.19
1.00 ± 0.00
1.02 ± 0.16
1.07 ± 0.29
1.04 ± 0.21
1.02 ± 0.15
1.02 ± 0.14

46.22 ± 11.78
41.39* ± 4.81
49.09* ± 7.76
9.41* ± 0.19
6.40* ± 0.57
16.29* ± 3.07
7.77* ± 0.18
3.51 ± 0.72
0.07* ± 0.02
0.15* ± 0.03
0.12* ± 0.02

17.45* ± 2.18
19.81* ± 2.26
15.02* ± 1.09
5.00* ± 0.56
4.22* ± 0.32
15.06* ± 0.54
5.64* ± 0.70
2.34 * ± 0.23
0.14* ± 0.04
0.26* ± 0.05
0.17* ± 0.02

10.92* ± 1.40
11.53 ± 3.04
5.81 ± 1.27
0.60 ± 0.09
0.94 ± 0.17
2.18* ± 0.15
3.87* ± 0.34
2.56* ± 0.35
0.34* ± 0.05
0.28* ± 0.09
0.24* ± 0.02

5.52 ± 3.39
9.82 ± 2.10
7.09* ± 1.02
2.20 ± 0.48
1.25 ± 0.11
3.51 ± 0.59
3.31 ± 1.48
2.01 ± 0.78
0.18* ± 0.17
0.13* ± 0.01
0.14* ± 0.03

0.24 ± 0.14
0.12 ± 0.04
1.32* ± 0.07
0.87 ± 0.00
0.25 ± 0.00
2.42 ± 0.00
0.29* ± 0.11
0.50 ± 0.00
0.03* ± 0.01
0.12* ± 0.00
0.02* ± 0.01

0.0003
b 0.001
b 0.001
b 0.001
b 0.001
b 0.001
b 0.001
0.0107
0.0005
b 0.001
b 0.001

Values shown are fold change (mean ± s.e.m.) calculated relative to 0 wk No cuprizone condition. N = 3 mice per condition with samples run across 3 plates as technical triplicates.
ANOVA values are for comparison across all time points for a given gene. Asterisks show signiﬁcant changes (p b 0.05) for individual time points using a one sample t-test comparison
to a theoretical mean of 1.000, i.e. null hypothesis for no fold change.
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Fig. 3. Plp/CreERT line applicability across stages of the oligodendrocyte lineage. Plp/CreERT mice were crossed to Z/AP reporter mice (A) or ﬂoxed Pdgfrα mice (B–E), administered
tamoxifen at 4 wks of age, and perfused at 6 wks of age (see Fig. 1A). Plp/CreERT:Z/AP mice demonstrate recombination and alkaline phosphatase (AP) reporter localization in
myelinated tracts (A). Immunohistochemistry within white matter from Plp/CreERT:Pdgfrαﬂ/ﬂ mice shows co-localization (arrows show two examples) of Cre recombinase protein in
oligodendrocytes identiﬁed by CC1 antibody (B–D). Quantiﬁcation of immunohistochemistry shows that tamoxifen administration in Plp/CreERT:Pdgfrαﬂ/ﬂ mice reduces coexpression of PDGFαR among oligodendrocyte progenitors, identiﬁed by NG2 immunolabeling (E, p = 0.0002, N = 3 mice of each condition). Scale bar = 500 μm (A) and 25 μm (D).

transcripts showed signiﬁcant reduction of oligodendrocytes in the CC
of mice receiving either tamoxifen or oil after 12 wks of cuprizone
(p b 0.001; Figs. 5A–C), indicating similar oligodendrocyte loss.
Furthermore, immunohistochemistry for myelin oligodendrocyte
glycoprotein (MOG) to detect myelinated areas indicated similar
demyelination at 12 wks of cuprizone (p b 0.001 compared to no

cuprizone; Figs. 5D–F). After the 6-wk recovery period, tamoxifen
treated mice exhibited extensive repair capacity based on both
recovery of oligodendrocytes (p N 0.05 vs no cuprizone; Figs. 5A–C) and
normalization of MOG values (p N 0.05 vs no cuprizone; Figs. 5D–F). In
contrast, after the 6-wk period on normal chow, vehicle-treated mice
continued to exhibit oligodendrocyte loss (p b 0.001 vs no cuprizone;

Fig. 4. Reduction of FGFR1 expression in oligodendrocyte progenitor (OP) cells. Analysis of coronal sections of corpus callosum from Plp/CreERT:Fgfr1ﬂ/ﬂ mice administered tamoxifen
(Tam) or vehicle (Oil) after 10 wks of cuprizone (see Fig. 1B) and then perfused at the end of 12 wks of cuprizone (A–G) or after a 6-wk recovery period without cuprizone in the diet
(G). Arrow indicates OP cells identiﬁed by NG2 immunolabeling (A, green; B) with co-localization of FGFR1 (A, red; C) in the corpus callosum (outlined by dash marks in A) after
12 wks of cuprizone in mice administered oil. FGFR1 expression is reduced among NG2 cells in mice administered tamoxifen compared with oil (D, p = 0.0105, N = 5 mice of each
condition). Example of OP cells, identiﬁed by in situ hybridization for PDGFαR (blue-black NBT-BCIP substrate) combined with immunostaining for BrdU (brown DAB substrate)
incorporated during a 4-h terminal pulse at 12 wks of cuprizone (E; oil control mouse shown). Tamoxifen treatment does not signiﬁcantly alter the population of PDGFαR + cells
labeled with BrdU at 12 wks of cuprizone (F). Quantiﬁcation of total PDGFαR + cells after 12 wks of cuprizone (12 wk) or after 12 wks of cuprizone followed by a 6-wk recovery
period (Recovery). Tamoxifen treated mice showed a reduction of total OP cells only after the recovery period (G; p b 0.05 for tamoxifen versus oil after 12 wks of cuprizone and
6 wks on normal chow; N = 5 mice of each condition for both 12 wk and recovery time points). Scale bars = 25 μm for A–C (shown in C) and for E.
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Fig. 5. Reduced FGFR1 expression increases oligodendrocyte repopulation of lesions and promotes remyelination following chronic demyelination. Plp/CreERT:Fgfr1ﬂ/ﬂ mice were
administered vehicle (Oil; A, D) or tamoxifen (Tam; B, E) after 10 wks of cuprizone and then perfused at the end of 12 wks of cuprizone or after a 6-wk recovery period without
cuprizone in the diet (see Fig. 1B). Images of coronal sections through the CC showing oligodendrocytes (A, B), identiﬁed by in situ hybridization for proteolipid protein (PLP) and
myelin (D, E), immunostained for myelin oligodendrocyte glycoprotein (MOG), in mice perfused after 12 wks of cuprizone followed by 6 wks on normal chow. Quantiﬁcation of
oligodendrocytes in the CC using unbiased stereology (C; N = 3–4 mice per condition). Oligodendrocyte loss is signiﬁcant in both tamoxifen and oil treated mice (*p b 0.001 vs no
cuprizone for each condition). During the recovery period, tamoxifen treated mice show enhanced repopulation of lesion areas (p N 0.05 vs no cuprizone) as compared to vehicle
controls (*p b 0.001 vs no cuprizone)). The percent area of the CC with MOG immunoreactivity above threshold (based on non-demyelinated dorsal fornix) serves as an estimate of
the myelinated area (F; N = 3 mice per condition). Mice administered tamoxifen or oil shows similar extents of demyelination after 12 wks of cuprizone (F, *p b 0.001 vs no
cuprizone, N = 3 mice of each condition). During the recovery period after chronic demyelination, mice administered tamoxifen have a signiﬁcant improvement with normalization
of the myelinated area (p N 0.05 vs. no cuprizone) as compared to the continued presence of demyelinated area in the vehicle controls (*p b 0.01 vs no cuprizone). Scale bars in A,
D = 250 μm.

Figs. 5A–C) and chronic demyelination (pb 0.001 vs no cuprizone;
Figs. 5D–F). This difference in MOG immunolabeling after the 6-wk
recovery indicates differential remyelination and is not the result of less
demyelination having occurred since both tamoxifen and oil treated
mice have approximately 50% of the CC area immunolabeled for MOG at
the end of the 12 wks of cuprizone (Fig. 5F). These ﬁndings demonstrate
that reduced expression of FGFR1 resulted in enhanced oligodendrocyte
repopulation and remyelination in the CC following chronic
demyelination.
Ultrastructural analysis of FGFR1 impact on myelin and axons during
chronic demyelination
To further explore the potential role of FGFR1 at the earliest stages of
remyelination, Plp/CreERT:Fgfr1ﬂ/ﬂ mice were treated with tamoxifen at
8 wks of cuprizone, continued on cuprizone through 12 wks and then
perfused for electron microscopy (Figs. 1C, 6A–B). This protocol allows
examination of a cycle of OP proliferation and repopulation that occurs
during the late stage of continued cuprizone treatment even before

returning the mice to normal chow (Armstrong et al., 2006; Mason et al.,
2004). In addition, electron microscopy can detect enhanced remyelination at an earlier stage than MOG immunolabeled area measurements
(Tobin et al., 2011). In wild type mice that have not been treated with
cuprizone, approximately 80% of axons over 0.3 μm in diameter are
myelinated in the caudal CC, as we have previously reported (Tobin
et al., 2011) and conﬁrmed in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice (82.75 ± 1.46).
Axons with diameters less than 0.3 μm may involve unmyelinated
axons and so are excluded. In Plp/CreER T:Fgfr1 ﬂ/ﬂ mice prepared as in
Fig. 1C, the proportion of myelinated axons is increased to almost 60%
in tamoxifen treated mice as compared to less than 20% in Plp/CreER T:
Fgfr1 ﬂ/ﬂ mice administered oil (p b 0.0001; Fig. 6E). A reduced slope in
the relationship of myelin thickness to axon diameter (Fig. 6G) is
indicative of a signiﬁcant population of remyelinated ﬁbers. The
tamoxifen treated Plp/CreER T:Fgfr1 ﬂ/ﬂ mice show a signiﬁcantly
reduced slope (0.028 ± 0.002) indicative of remyelination when
compared to mice administered oil (0.054 ± 0.004; p b 0.0001) or
control Plp/CreER T:Fgfr1 ﬂ/ﬂ mice that were not fed cuprizone (0.046 ±
0.009; p = 0.013). In contrast, the myelinated ﬁbers remaining in the
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Fig. 6. Ultrastructural analysis of myelin and axons during chronic cuprizone treatment in Plp/CreERT:Fgfr1ﬂ/ﬂ mice with comparison to Plp/CreERT:Pdgfrαﬂ/ﬂ mice. Mice were
administered tamoxifen (Tam) or vehicle (Oil) after 8 wks of cuprizone and then perfused at the end of 12 wks of cuprizone treatment (Fig. 1C). Electron micrographs of Plp/CreERT:
Fgfr1ﬂ/ﬂ mice administered oil (A) or tamoxifen (B) and Plp/CreERT:Pdgfrαﬂ/ﬂ mice administered oil (C) or tamoxifen (D). Quantiﬁcation of myelin and axon parameters in Plp/CreERT:
Fgfr1ﬂ/ﬂ mice (E, G, I, J) or Plp/CreERT:Pdgfrαﬂ/ﬂ mice (F, H, K, L). The percent myelinated axons is signiﬁcantly greater in Plp/CreERT:Fgfr1ﬂ/ﬂ mice administered tamoxifen (E, p b 0.001,
similar results in each of two cohorts for total of N = 6 for Oil and N = 7 for Tam). The slope of myelin thickness relative to axon diameter is signiﬁcantly reduced in Plp/CreERT:Fgfr1ﬂ/ﬂ
mice administered tamoxifen (G, p b 0.001). Overall mean values of both myelin thickness and axon diameter are increased in Plp/CreERT:Fgfr1ﬂ/ﬂ mice administered tamoxifen (I,
p b 0.001; J, p = 0.0018). The percent myelinated axons is not signiﬁcantly different for Plp/CreERT:Pdgfrαﬂ/ﬂ mice treated with oil or tamoxifen (p = 0.614; N = 4 mice of each
condition). Overall mean values of myelin thickness are slightly higher with tamoxifen treatment in Plp/CreERT:Pdgfrαﬂ/ﬂ mice (K, p = 0.0188) while axon diameters are decreased (L,
p = 0.0058). Scale bar = 1 μm.

oil treated mice probably were never demyelination based on the
similarity of the slope to that of the mice which were not fed
cuprizone. Average axon diameters were increased in the Plp/CreER T:
Fgfr1 ﬂ/ﬂ mice administered tamoxifen, indicating a potential beneﬁt
of remyelination to axon integrity (p = 0.0018; Fig. 6J).

Analysis of Plp/CreER T:Pdgfrα ﬂ/ﬂ mice demonstrates speciﬁcity of FGFR1
effect
Plp/CreER T:Pdgfrα ﬂ/ﬂ mice were tested for expected differential
effects from Plp/CreERT:Fgfr1ﬂ/ﬂ mice. PDGFαR is expressed on OP cells,
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including OP cells that continue to proliferate after 12 wks of cuprizone
(Figs. 4E, F). Pdgfrα haploinsufﬁciency results in reduced oligodendrogenesis during remyelination from cuprizone (Murtie et al., 2005b),
which would be counter to the current results in Plp/CreERT:Fgfr1ﬂ/ﬂ
mice (Fig. 5). In Plp/CreERT:Pdgfrαﬂ/ﬂ mice, approximately 20% of axons
were myelinated in mice administered either tamoxifen or oil
(p= 0.614; Fig. 6F). The quantiﬁcation of axon and myelin parameters
in the Plp/CreERT:Pdgfrαﬂ/ﬂ mice is consistent with a low proportion of
remyelinated ﬁbers (Fig. 6 H, K, L). This result clearly demonstrates that
tamoxifen treatment during chronic demyelination in Plp/CreER T:
Pdgfrαﬂ/ﬂ mice (Fig. 6F) did not have the same effect on remyelination
as was observed in Plp/CreERT:Fgfr1ﬂ/ﬂ mice (Fig. 6E). Furthermore, the
results show that values in the oil treated condition of both Plp/CreERT:
Pdgfrαﬂ/ﬂ mice and Plp/CreERT:Fgfr1 ﬂ/ﬂ mice are fairly similar (Figs. 6E, F)
which supports the distinction of an effect of FGFR1 deletion with
tamoxifen administration.
Analysis of neuroﬁlament dephosphorylation as an indicator of axon
damage
Chronic cuprizone demyelination results in axon damage which can
be evaluated by ultrastructural analysis (Fig. 6) and more readily
quantiﬁed by immunohistochemical detection of dephosphorylated
neuroﬁlaments (Xie et al., 2010; Tobin et al., 2011). To examine the
effect of FGFR1 on axon damage in conjunction with the effects on
remyelination, Plp/CreERT:Fgfr1ﬂ/ﬂ mice were administered tamoxifen or
oil at 8 wks of cuprizone, continued on cuprizone through 12 wks and
then perfused (Fig. 1C). Parasagittal sections of the corpus callosum
were double immunolabeled for SMI32 (dephosphorylated neuroﬁlaments indicative of damaged axons) and for NF200 (neuroﬁlaments
regardless of phosphorylation state indicative of total axon population)
(Fig. 7). Plp/CreERT:Fgfr1ﬂ/ﬂ mice administered oil showed a marked
proportion of axons immunolabeled for SMI32 which is consistent with
our previous studies of wild type mice (Xie et al., 2010; Tobin et al.,
2011). In contrast, Plp/CreERT:Fgfr1ﬂ/ﬂ mice administered tamoxifen
showed over a 44% reduction in the proportion of SMI32 immunolabeled axons. This signiﬁcant (p= 0.0207) difference indicated attenuation of axon damage during chronic demyelination associated with
tamoxifen deletion of Fgfr1 in oligodendrocyte lineage cells.
Discussion
The current study identiﬁes FGFR1 as a key component regulating
remyelination. Tamoxifen-induced reduction of FGFR1 expression in OP

Fig. 7. Analysis of axon damage during chronic cuprizone treatment in Plp/CreERT:
Fgfr1ﬂ/ﬂ mice. A–B: Representative confocal microscopy images of double immunolabeling with NF200 (green; pan-neuroﬁlament marker) and SMI32 (red; nonphosphorylated neuroﬁlament epitope) in the caudal CC of Plp/CreERT:Fgfr1ﬂ/ﬂ mice
administered oil (A) or tamoxifen (B). Co-labeled axons appear yellow. C: Quantiﬁcation of the proportion of SMI32 labeled axons in the CC relative to the total number of
axons identiﬁed by SMI32 and/or NF200. After 12 wks of cuprizone, signiﬁcantly fewer
axons are immunolabeled for SMI-32 in Plp/CreER T:Fgfr1ﬂ/ﬂ mice administered
tamoxifen as compared to oil (p = 0.0207; N = 4 mice of each condition). Scale
bar = 20 μm.

cells that persist during chronic demyelination resulted in enhanced
oligodendrogenesis and remyelination. Electron microscopy conﬁrmed
that a greater proportion of demyelinated axons underwent spontaneous
remyelination in Plp/CreER T:Fgfr1ﬂ/ﬂ mice administered tamoxifen.
Corresponding changes in the OP cell population relative to the
oligodendrocyte population, in the absence of changes in BrdU labeling,
indicate that FGFR1 impacts remyelination through regulating OP
differentiation and not through modulation of OP proliferation. Furthermore, reduction of FGFR1 expression in oligodendrocyte lineage cells
reduced the extent of axon damage which demonstrates a signiﬁcant
positive effect of oligodendrogenesis and remyelination on axon integrity
in a model of chronic demyelination.
The cuprizone model facilitates identiﬁcation of speciﬁc cellular and
molecular interactions that regulate the OP response and capacity to
repair chronically demyelinated axons. After removing the cuprizone
neurotoxicant, remyelination can be examined more speciﬁcally than
in other models of chronic demyelination with ongoing disease
pathogenesis. The lack of a persistent immune demyelinating component aids in the identiﬁcation of signaling effects on remyelination
processes that are not overshadowed by effects on the immune disease
severity. However, studies across multiple experimental models of
demyelinating disease are important for analysis in the context of a
broader range of pathological features of MS. For example, murine
hepatitis virus strain A59 (MHV-A59) infection creates a more complex
lesion environment, with pathogenic infection followed by an
inﬂammatory response that clears the virus. Analysis of MHV-A59
lesions in Fgf2 null mice showed increased oligodendrocyte repopulation of demyelinated lesions (Armstrong et al., 2002). Therefore, the
FGF signaling pathway has a robust effect on oligodendrocyte lineage
cells in diverse models of demyelinating disease.
The Plp/CreER T line employs sequences of transcriptional control of
the mPlp gene that are well characterized to drive expression within
the oligodendrocyte lineage from OP cells to mature oligodendrocytes
(Fuss et al., 2000; Doerﬂinger et al., 2003). The Plp/CreER T line was
selected to target OP cells leading to remyelination and therefore may
be more aligned for the current studies than other lines, such as those
driven by NG2 transcription. Accordingly, the present studies
demonstrated deletion of Fgfr1 and Pdgfra in approximately a third
of NG2 cells (Figs. 3 and 4). This deletion efﬁciency in the current
studies may reﬂect reduced access of tamoxifen into in the adult CNS,
the lower level of PLP transcription in OP cells, or the efﬁciency of Cre
activity with these particular crossed lines. However, the tamoxifen
administration effectively revealed signiﬁcant differences relevant to
remyelination in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice using multiple analysis
techniques.
The effect of conditional inducible reduction of FGFR1 on
remyelination is dependent upon the actions of endogenous ligands
that can activate FGFR1 in this chronic lesion environment. Multiple
FGF family ligands are present and/or upregulated during chronic
cuprizone demyelination and recovery (Fig. 1, Table 1). FGFR1
expression clusters with expression of FGF2 and FGF12 ligands
(Fig. 1). Previous studies support FGF2 among the FGF family
members as being a relevant ligand for FGFR1 regulation of OP
differentiation. Using neonatal rat OP cultures, we showed that FGF2
inhibition of OP differentiation was disrupted by RNA interference
knockdown of FGFR1 but not FGFR2 or FGFR3 (Zhou et al., 2006).
FGF12 is not a likely signaling partner with FGFR1 since FGFs 11–14
function as intracellular proteins that act independently of FGFRs
(Itoh and Ornitz, 2008). Among the other FGF ligands, only FGF1, 8, 17,
and 18 have been reported to regulate OP differentiation in neonatal
rat cultures (Fortin et al., 2005; Prendaj et al., 2010). However,
members of the FGF8 subfamily (FGF8, 17, and 18) have been
reported to act through FGFR3, and not FGFR1 (Fortin et al., 2005).
FGF7 interacts only with the IIIb splice variant of FGFR2 (Rubin et al.,
1995). Although FGF1 can activate all FGFR forms, FGF1 levels are
decreased throughout cuprizone demyelination and recovery stages
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relative to non-treated mice, suggesting that FGF1 is not likely to be a
predominant ligand in this lesion environment (Fig. 1).
The similarity of results from analysis of Fgf2 null mice with the
current results in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice administered tamoxifen
provides further support of the potential mechanism of FGF2 signaling
through FGFR1 to regulate the efﬁciency of OP differentiation,
oligodendrogenesis, and remyelination. In the contexts of developmental myelination and during remyelination following cuprizone
mediated CC demyelination, retroviral lineage tracing showed a
signiﬁcant increase in the frequency of OP differentiation into
oligodendrocytes in Fgf2 null mice compared to wild type mice
(Murtie et al., 2005a; Murtie et al., 2005b). Consistent with the current
results (Fig. 5), Fgf2 null mice showed increased oligodendroglial
repopulation of lesions following either acute or chronic cuprizone
mediated demyelination (Armstrong et al., 2006; Armstrong et al.,
2002). This increase of oligodendrocytes was not likely to be due to an
effect on OP proliferation as BrdU incorporation was not altered in
Fgf2 null mice (Armstrong et al., 2006; Armstrong et al., 2002), which
also corresponds well with our analysis in Plp/CreER T:Fgfr1 ﬂ/ﬂ mice
administered tamoxifen (Fig. 4). Finally, both Fgf2 null mice and
Plp/CreER T:Fgfr1 ﬂ/ﬂ mice administered tamoxifen show dramatically
improved remyelination following chronic cuprizone treatment using
both MOG immunolabeling to estimate the area myelinated (Fig. 5)
and electron microscopy to measure the proportion of myelinated
axons (Fig. 6) (Armstrong et al., 2006; Tobin et al., 2011).
Our studies in Fgf2 null mice demonstrated an important role of
FGF2 signaling on remyelination but the constitutive knockout design
could not distinguish among potential cell types involved and could
not demarcate the effective disease stage. FGF2 is synthesized by
reactive astrocytes and microglia/macrophage cells in demyelinated
lesions (Messersmith et al., 2000). In situ hybridization detection of
FGF2 demonstrated that relatively low FGF2 levels in the normal adult
corpus callosum are markedly increased during acute cuprizone
demyelination and maintained at elevated levels during chronic
cuprizone demyelination (Armstrong et al., 2006; Armstrong et al.,
2002), which was quantitatively shown by the current PCR analysis
(Fig. 2). FGF2 inhibition of OP differentiation occurs during acute
demyelination and remyelination, as demonstrated by retroviral
lineage tracing (Murtie et al., 2005b). However, during acute cuprizone
demyelination OP cells are ampliﬁed approximately ﬁve-fold whereas
following chronic cuprizone demyelination only low levels of OP cells
are available to carry out remyelination (Armstrong et al., 2006)
(Fig. 4G). Therefore, the dramatic effect of FGF2 on remyelination
following chronic demyelination may reﬂect the importance of FGF2
inhibition of OP differentiation when the pool of OP cells is limited.
The tamoxifen inducible approach used to reduce FGFR1 expression now speciﬁcally targets the chronic demyelination period and
demonstrates a strong effect on remyelination (Figs. 5 and 6). This
conditional approach used to reduce FGFR1 expression now also
demonstrates that the increased remyelination involves a direct role
of FGFR1 in OP cells and oligodendrocytes (Figs. 4 and 5). Although
FGF2 may also act through astrocytes to regulate remyelination,
preliminary experiments in GfapCreERT2:Fgfr1 ﬂ/ﬂ mice did not show
an increase of remyelinated ﬁbers with tamoxifen administration
(unpublished data). Importantly, our studies in Fgf2 null mice showed
reduced axon damage compared to Fgf2 wt mice but could not
distinguish direct or indirect effects of FGF2 on axons (Tobin et al.,
2011). The current studies (Fig. 7) now demonstrate reduced axon
damage that is accomplished through an indirect effect on axons.
Speciﬁcally, improved axon integrity corresponds with increased
oligodendrogenesis and remyelination from reduced FGFR1 expression in oligodendrocyte lineage cells.
The speciﬁc examples of FGF2 and FGFR1 impacting remyelination
may relate to a more general concept that demyelinated lesions
contain signals that inhibit OP differentiation and limit remyelination.
Multiple signals in lesions may inhibit oligodendrocyte lineage cells at
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different stages of maturation and myelin formation. Lingo1 appears
to interact with nerve growth factor receptors on oligodendrocytes or
axons to inhibit oligodendrocyte process extension and myelination
(Bourikas et al., 2010; Lee et al., 2007). Antagonism of Lingo1
promotes OP cell differentiation and remyelination (Mi et al., 2009).
Notch1 is also a potent inhibitor of OP cell differentiation and genetic
reduction of Notch1 expression in oligodendrocyte lineage cells
increases remyelination (Zhang et al., 2009). Interestingly, FGF2
may interact with mastermind-like 1 and Hes5 components of the
notch signaling pathway for inhibition of OP differentiation (Zhou and
Armstrong, 2007). Lingo1 and Notch1 signaling pathways have not
yet been manipulated in the context of a chronic course of
demyelination to test effects on repair capacity from a limited pool
of OP cells.
Conclusions
The current studies support development of therapeutic strategies
to modify the tissue environment following CNS injury or disease to
optimize the repair potential of endogenous cells. Speciﬁcally,
reducing expression of signaling pathways that inhibit OP cell
differentiation into oligodendrocytes can dramatically improve
remyelination and axon integrity even in a chronic demyelination
model. FGF2 and FGFR1 are identiﬁed as relevant signaling components limiting remyelination. The pleiotrophic effects of FGF2 create
an unfavorable proﬁle for therapeutic development while exploiting
the role of speciﬁc isoforms of FGFR1 to directly impact oligodendrocyte lineage cell responses may be advantageous.
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